

Singapore-based startup Allozymes partners with GenScript to accelerate enzyme discovery

09 December 2022 | News

Partnership teams one of the world's top gene providers with the fastest enzyme engineering platform

GenScript Biotech Corporation, the world's leading provider of life-science research tools and services, is partnering with Allozymes, a Singapore-based biotech startup, to dramatically accelerate the enzyme discovery and development process.

GenScript will provide the mutant libraries construction and expression, while Allozymes will provide ultra-high-throughput screening service for applications across various industries, including pharmaceuticals, cosmetics, and food and beverage.

Naturally occurring enzymes and microbes are frequently used not only for biomedical purposes but also in the field of biotechnology. The development of synthetic biology, through protein and metabolic engineering, has provided a solution to engineer custom microbes into cell factories that can massively produce not only the natural products but also a product with improved properties. This approach involves the generation of mutant libraries followed by a high-throughput screening technology.

GenScript's strong expertise in *de novo* gene synthesis and its semiconductor-based oligo-synthesis technology provides the foundation for a Precision Mutant Library service that offers precise control over each synthesised variant. The result is a diverse and comprehensive mutant library with unbiased distribution.